KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead
KOMZIFTI is rapidly gaining market share in acute leukemia, supported by strong efficacy, safety, and payer access. Multiple phase III trials and data updates are underway, with expansion into diabetes and solid tumors through new ventures and partnerships.Based on Kura Oncology, Inc. [KURA] 12th A…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.